The OpenFold Consortium has experienced growth with the recent addition of eleven new members, including notable names like Absci and Adaptive Biotechnologies. This expansion highlights a commitment to developing open-source AI models for drug discovery and biological research, an area increasingly dependent on advanced computational tools.
Founded as a nonprofit initiative, the consortium seeks to create a foundation for high-performing AI models that are openly accessible to the scientific community. The influx of new members strengthens the consortium’s collaborative network, which encompasses academic institutions and industry players focused on various life sciences aspects, including therapeutic discovery and antibody design.
Woody Sherman, Chair of the Executive Committee, expressed enthusiasm about the new members, stating that their involvement reflects the extensive ecosystem forming around open biomolecular AI. "OpenFold is becoming shared infrastructure for the next generation of AI-enabled drug discovery," he said. This statement underscores the consortium's aim to establish a transparent and extensible framework that can advance drug discovery processes.
The demand for open, extensible models is urgent. While AI-driven structure prediction tools are making progress, many complex biological challenges persist. The consortium seeks to move beyond static models to incorporate capabilities like molecular recognition and protein design, ultimately improving workflows in drug discovery. This mission aligns with the consortium's commitment to ensuring that these tools are rigorously benchmarked and accessible, enabling scientists to test and refine them collaboratively.
Among the new members, Absci stands out with its innovative generative AI platform tailored for therapeutic antibody design. Amir Shanehsazzadeh, Chief AI Officer at Absci, expressed excitement about collaborating with OpenFold, stating, "We've been delighted to work with the OpenFold team and support their efforts to achieve state-of-the-art performance on antibody-antigen folding." This partnership is particularly vital given the complexities surrounding antibody design in drug discovery.
Adaptive Biotechnologies also highlights the potential of open-source models to revolutionize the understanding of the adaptive immune system. Harlan Robins, Chief Scientific Officer, remarked, "Adaptive Biotechnologies is excited to be joining the OpenFold Consortium and to support the development of open-source models of biomolecular structure and interaction." Their focus on translating genetic information into clinical applications illustrates the consortium's broad applicability across various research domains.
Benchling, a leading AI platform for biotech R&D, is another key addition. With over 1,300 biotech companies using its platform, Benchling’s new Model Hub allows scientists to integrate predictive models like OpenFold2 directly into their workflows. This capability connects computational predictions with experimental outcomes, a crucial step in advancing drug discovery.
The inclusion of organizations such as Chemical Computing Group further solidifies the consortium's influence in the drug discovery field. Known for its MOE platform, this company provides comprehensive tools for modeling and simulations, enhancing the capabilities available through OpenFold.
As the consortium expands, its impact on the future of drug discovery and biological research is likely to be significant. By promoting collaboration and open-source development, OpenFold accelerates research and ensures that innovations are shared and built upon collectively, allowing for a more dynamic and effective approach to addressing some of the most challenging problems in biology.
The growing membership of the OpenFold Consortium marks a pivotal moment in the integration of AI and biology, aiming for breakthroughs that transcend individual capabilities and unite diverse expertise for the benefit of the entire scientific community.
The stories that move AI & crypto markets — before the market reacts.
Free. 7am ET. Five stories. 62,400 readers.
